# DR Reddys Laboratories Ltd: overview RDY · NYSE · CIK 1135951 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Mar 31 Pages: [Overview](/companies/rdy.md) · [Financials](/companies/rdy/financials.md) · [Filings](/companies/rdy/filings.md) · [Insiders](/companies/rdy/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY2021 (2021-03-31) | FY2022 (2022-03-31) | FY2023 (2023-03-31) | FY2024 (2024-03-31) | FY2025 (2025-03-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [2,594](/filings/0001575872-21-000138.md) | [2,826](/filings/0001575872-22-000576.md) | [2,992](/filings/0001575872-23-000951.md) | [3,350](/filings/0001575872-24-000660.md) | [3,811](/filings/0001575872-25-000393.md) | | Gross margin | % | [54.3%](/filings/0001575872-21-000138.md) | [53.1%](/filings/0001575872-22-000576.md) | [56.7%](/filings/0001575872-23-000951.md) | [58.6%](/filings/0001575872-24-000660.md) | [58.5%](/filings/0001575872-25-000393.md) | | Operating margin | % | [12.8%](/filings/0001575872-21-000138.md) | [13.8%](/filings/0001575872-22-000576.md) | [23.2%](/filings/0001575872-23-000951.md) | [24.3%](/filings/0001575872-24-000660.md) | [22.1%](/filings/0001575872-25-000393.md) | | Net margin | % | [9.1%](/filings/0001575872-21-000138.md) | [11.0%](/filings/0001575872-22-000576.md) | [18.3%](/filings/0001575872-23-000951.md) | [19.9%](/filings/0001575872-24-000660.md) | [17.4%](/filings/0001575872-25-000393.md) | | Diluted EPS | $ per share | [1.52](/filings/0001575872-21-000138.md) | [1.87](/filings/0001575872-22-000576.md) | [3.30](/filings/0001575872-23-000951.md) | [4.01](/filings/0001575872-24-000660.md) | [0.79](/filings/0001575872-25-000393.md) | | Free cash flow | $m | [355](/filings/0001575872-21-000138.md) | [177](/filings/0001575872-22-000576.md) | [578](/filings/0001575872-23-000951.md) | [348](/filings/0001575872-24-000660.md) | [223](/filings/0001575872-25-000393.md) | - Revenue. XBRL Revenue: ifrs-full:Revenue. - Gross margin (gross profit / revenue). XBRL Gross profit: ifrs-full:GrossProfit; Revenue: ifrs-full:Revenue. - Operating margin (operating income / revenue). XBRL Operating income: ifrs-full:ProfitLossFromOperatingActivities; Revenue: ifrs-full:Revenue. - Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLoss; Revenue: ifrs-full:Revenue; Net income: ifrs-full:ProfitLossAttributableToOwnersOfParent. - Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/rdy/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Robeco Institutional Asset Management B.V.](/funds/1418773.md) | 2026-06-30 | $261.1m | 18,021,100 | | Added +843,218 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $158.5m | 10,936,320 | | Added +1,564,726 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $153.4m | 10,585,742 | | Reduced −1,001,385 | | [ROYAL BANK OF CANADA](/funds/1000275.md) | 2026-06-30 | $133.5m | 9,213,269 | | Reduced −770,813 | | [Aikya Investment Management Ltd](/funds/2005403.md) | 2026-06-30 | $123.1m | 8,493,852 | | Added +494,056 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $106.5m | 7,347,028 | | Reduced −512,700 | | [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $77.0m | 5,312,065 | | Reduced −11,183 | | [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $60.5m | 4,069,357 | | Reduced −302,021 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $59.8m | 4,124,686 | | Added +98,479 | | [ALLIANCEBERNSTEIN L.P.](/funds/1109448.md) | 2026-06-30 | $51.7m | 3,730,713 | | Added +1,188,824 | ## Recent filings [All 1,213 filings](/companies/rdy/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-29 | 14:39 ET | [6-K](/filings/0001575872-26-000745.md) | Report of a foreign private issuer, period 2026-10-29 | 0001575872-26-000745 | | 2026-10-29 | 21:37 ET | [6-K](/filings/0001575872-26-000743.md) | Report of a foreign private issuer, period 2026-10-28 | 0001575872-26-000743 | | 2026-10-26 | 06:22 ET | [6-K](/filings/0001575872-26-000732.md) | Report of a foreign private issuer, period 2026-10-24 | 0001575872-26-000732 | | 2026-10-26 | 06:18 ET | [6-K](/filings/0001575872-26-000730.md) | Report of a foreign private issuer, period 2026-10-24 | 0001575872-26-000730 | | 2026-10-23 | 14:43 ET | [6-K](/filings/0001575872-26-000725.md) | Report of a foreign private issuer, period 2026-10-23 | 0001575872-26-000725 | | 2026-10-23 | 14:15 ET | [6-K](/filings/0001575872-26-000724.md) | Report of a foreign private issuer, period 2026-10-23 | 0001575872-26-000724 | | 2026-10-23 | 14:02 ET | [6-K](/filings/0001575872-26-000721.md) | Report of a foreign private issuer, period 2026-10-23 | 0001575872-26-000721 | | 2026-10-23 | 12:22 ET | [6-K](/filings/0001575872-26-000719.md) | Report of a foreign private issuer, period 2026-10-23 | 0001575872-26-000719 | | 2026-10-21 | 06:21 ET | [6-K](/filings/0001575872-26-000715.md) | Report of a foreign private issuer, period 2026-10-21 | 0001575872-26-000715 | | 2026-10-14 | 12:43 ET | [6-K](/filings/0001575872-26-000700.md) | Report of a foreign private issuer, period 2026-10-14 | 0001575872-26-000700 | ## Latest annual report [Form 20-F for the fiscal year ended Mar 31, 2026](/filings/0001575872-26-000381.md), filed May 29, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1135951 - Tickers: RDY - Exchange: NYSE - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: K7 - Filer category: Large accelerated filer Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 14:40 ET. No prices; not investment advice.